Sanofi SA

1SAN

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

stocks

Nvidia Earnings: No signs of a slowdown in demand for AI chips

A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks

ASX results reaction: WiseTech, Woolies, Sigma and more

A round up of notable stories and reactions as ASX reporting season rolls on.
stocks

WiseTech result disappoints, but the future looks bright

Markets appear underwhelmed by recent sales growth, however, our kingmaker thesis is intact.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,243.009.000.10%
CAC 407,703.9058.70-0.76%
DAX 4023,902.21137.71-0.57%
Dow JONES (US)45,544.8892.02-0.20%
FTSE 1009,187.3429.48-0.32%
HKSE25,077.6278.800.32%
NASDAQ21,455.55249.61-1.15%
Nikkei 22542,718.47110.32-0.26%
NZX 50 Index12,930.7327.650.21%
S&P 5006,460.2641.60-0.64%
S&P/ASX 2008,973.104.100.05%
SSE Composite Index3,857.9314.330.37%

Market Movers